Risk factors
Ocugen (OCGN) risk factors
Item 1A of every Ocugen, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors74 risks8 new12 dropped21 reworded
Added debt agreements with Avenue Capital and EB-5 Life Sciences totaling $30.0 million in principal.
Filed Mar 04, 2026 - FY2024 10-K risk factors78 risks
Ocugen faces high risk as a clinical-stage biotechnology company with no commercialized products and $58.5 million in cash as of December 31, 2024. The company is heavily dependent on the clinical success and regulatory approval of unproven platforms like modifier gene therapy and OCU200 biologics. Financial constraints require substantial additional funding, creating risks of dilution, clinical delays, or operational curtailment.
Filed Mar 05, 2025